

Patent Application
Attorney Docket No. 5950-01-CA

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method for preventing or delaying catheter-based revascularization in patients suffering from coronary artery disease and in need of such treatment consisting essentially of administering a cholesterol lowering agent in an amount effective to cause an aggressive lowering of LDL cholesterol; wherein the cholesterol lowering agent is an HMG-CoA reductase inhibitor; and wherein the HMG-CoA reductase inhibitor is atorvastatin, or a pharmaceutically acceptable salt thereof.

Claim 2 (canceled)


Claim 3 (canceled)

Claim 4 (canceled)

Claim 5 (currently amended): The method according to Claim 4-1 wherein the amount of atorvastatin administered is from about 50 mg/day to about 150 mg/day.

Claim 6 (original): The method according to Claim 5 wherein atorvastatin is administered at a dose of about 80 mg/day.

Claim 7 (currently amended): A method ~~according to Claim 1~~ for preventing or delaying catheter-based revascularization in patients suffering from coronary artery disease and in need of such treatment consisting essentially of administering a cholesterol lowering agent in an amount effective to cause an aggressive lowering of LDL cholesterol; wherein the cholesterol lowering agent is a carboxyalkyl ether of the formula



Patent Application
Attorney Docket No. 5950-01-CA

wherein n and m independently are integers from 2 to 9;
or a pharmaceutically acceptable salt thereof.

Claim 8 (original): The method according to Claim 7 wherein the cholesterol lowering agent administered is 6,6'-oxybis-(2,2-dimethylhexanoic acid), or a pharmaceutically acceptable salt thereof.

Claim 9 (currently amended): A method ~~according to Claim 1~~ for preventing or delaying catheter-based revascularization in patients suffering from coronary artery disease and in need of such treatment consisting essentially of administering a cholesterol lowering agent in an amount effective to cause an aggressive lowering of LDL cholesterol; wherein the cholesterol lowering agent is selected from a fibrate.

E¹
Cncl

Claim 10 (previously presented): The method according to Claim 9 wherein the cholesterol lowering agent is selected from clofibrate, gemfibrozil, fenofibrate, ciprofibrate, and bezafibrate.